Get started
Author

Sergey Yagoda

Observed names: S Yagoda, S. A. Yagoda, S. Yagoda, Sergey Yagoda (11540846), Yagoda Sergey, Yagoda, Sergey, С.А. Ягода
ORCID: 0000-0002-4103-4827
Observed ORCID: 0000-0002-4103-4827
OpenAlex ID: A5073592161
A phase 3, multicenter study to assess the 1-year safety and tolerability of a combination of olanzapine and samidorphan in patients with schizophrenia: Results from the ENLIGHTEN-2 long-term extension
2021 · René S. Kahn, Bernard L. Silverman, et al. · Schizophrenia Research · 43
PDF
Long-term safety and durability of effect with a combination of olanzapine and samidorphan in patients with schizophrenia: results from a 1-year open-label extension study
2020 · Sergey Yagoda, Christine Graham, et al. · CNS Spectrums · 28
PDF
Reduction in Multiple Cardiometabolic Risk Factors With Combined Olanzapine/Samidorphan Compared With Olanzapine: Post Hoc Analyses From a 24-Week Phase 3 Study
2022 · Christoph U Correll, Evan Stein, et al. · Schizophrenia Bulletin · 24
PDF
Efficacy and Safety of a 2-Month Formulation of Aripiprazole Lauroxil With 1-Day Initiation in Patients Hospitalized for Acute Schizophrenia Transitioned to Outpatient Care
2020 · Peter J. Weiden, Amy Claxton, et al. · The Journal of Clinical Psychiatry · 22
Combination of Olanzapine and Samidorphan Has No Clinically Significant Effect on the Pharmacokinetics of Lithium or Valproate
2019 · Lei Sun, Sergey Yagoda, et al. · Clinical Drug Investigation · 19
PDF
Effect of hepatic and renal impairment on the pharmacokinetics of olanzapine and samidorphan given in combination as a bilayer tablet
2019 · Lei Sun, Sergey Yagoda, et al. · Drug Design Development and Therapy · 19
PDF
Olanzapine/Samidorphan in Young Adults With Schizophrenia, Schizophreniform Disorder, or Bipolar I Disorder Who Are Early in Their Illness
2023 · René S. Kahn, John M. Kane, et al. · The Journal of Clinical Psychiatry · 18
PDF
Combination of olanzapine and samidorphan has no clinically relevant effects on ECG parameters, including the QTc interval: Results from a phase 1 QT/QTc study
2020 · Lei Sun, Sergey Yagoda, et al. · Progress in Neuro-Psychopharmacology and Biological Psychiatry · 15
PDF
Olanzapine/samidorphan combination consistently mitigates weight gain across various subgroups of patients
2022 · Jonathan M. Meyer, Adam Simmons, et al. · CNS Spectrums · 10
PDF
Aripiprazole lauroxil 2-month formulation with 1-day initiation in patients hospitalized for an acute exacerbation of schizophrenia: exploratory efficacy and patient-reported outcomes in the randomized controlled ALPINE study
2021 · Henry A. Nasrallah, Peter J. Weiden, et al. · BMC Psychiatry · 10
PDF
O013 Preliminary Results from a Phase 1 Study of ALKS 2680, an Orexin-2 receptor Agonist, in Healthy Participants and Patients with Narcolepsy or Idiopathic Hypersomnia
2023 · B Yee, J Chapman, et al. · SLEEP Advances · 6
PDF
0838 The Orexin 2 Receptor Agonist ALKS 2680 in Patients with Narcolepsy or Idiopathic Hypersomnia: A Phase 1b Study
2025 · Ronald Grunstein, Brendon Yee, et al. · SLEEP · 4
PDF
Safety and Tolerability of Starting Aripiprazole Lauroxil With Aripiprazole Lauroxil NanoCrystal Dispersion in 1 Day Followed by Aripiprazole Lauroxil Every 2 Months Using Paliperidone Palmitate Monthly as an Active Control in Patients With Schizophrenia
2024 · Leslie Citrome, Sergey Yagoda, et al. · The Journal of Clinical Psychiatry · 4
PDF
Handwriting Kinematics in Patients with Schizophrenia Treated with Long-Acting Injectable Atypical Antipsychotics: Results From the ALPINE Study
2022 · Michael P Caligiuri, Peter J Weiden, et al. · Schizophrenia Bulletin Open · 4
PDF
The 4th Schizophrenia International Research Society Conference, 5–9 April 2014, Florence, Italy: A summary of topics and trends
2014 · Olukayode Abayomi, Davide Amato, et al. · Schizophrenia Research · 4
The Orexin 2 Receptor Agonist ALKS 2680 in Patients with Narcolepsy Type 1: An Initial Proof of Concept Phase 1b Study (P8-4.004)
2025 · Ron Grunstein, Brendon Yee, et al. · Neurology · 2
M105. Actigraphic Monitoring of Sleep-wake Cycle in Schizophrenia Outpatients Receiving a Long-acting Injectable Antipsychotic: Feasibility and Initial Results From a Prospective Rct
2020 · Sergey Yagoda, Robin Wolz, et al. · Schizophrenia Bulletin · 2
Targeting Orexin 2 Receptors in Idiopathic Hypersomnia and Narcolepsy: A Randomised Phase 1b Proof‐Of‐Concept Study of Alixorexton
2026 · Ronald R. Grunstein, Brendon J. Yee, et al. · Journal of Sleep Research · 1
Initiating Aripiprazole Lauroxil
2024 · Roger W. Sommi, Stephen R. Saklad, et al. · The Journal of Clinical Psychiatry · 1
PDF
Functioning and Cognition in Patients with Schizophrenia After Initiating Treatment with Aripiprazole Lauroxil: Secondary Outcomes and Post Hoc Analysis.
2024 · Mark G A Opler, Amy Claxton, et al. · PubMed Central · 1
PDF
Long-Term Antipsychotic Efficacy of Olanzapine and Samidorphan Combination in Patients With Schizophrenia: Pooled Analyses From Phase 3 Studies
2021 · Rene Kahn, Christine Graham, et al. · Biological Psychiatry · 1
Long-Term Weight and Metabolic Effects of Olanzapine and Samidorphan Combination in Patients With Schizophrenia: Pooled Analyses From Phase 3 Studies
2021 · John W. Newcomer, Ying Jiang, et al. · Biological Psychiatry · 1
Reduced Risk Across Multiple Cardiometabolic Risk Factors With OLZ/SAM Compared With Olanzapine: Results From a 24-Week Phase 3 Study
2021 · Christoph U. Correll, Evan Stein, et al. · Biological Psychiatry · 1
167 Randomized, Double-Blind, Active-Controlled Study of Starting Aripiprazole Lauroxil with 1-Day Initiation in Acutely Ill Patients with Schizophrenia
2020 · Peter J. Weiden, Amy Claxton, et al. · CNS Spectrums · 1
PDF
A case of familial thrombophilia in the patient with complicated peripartum cardiomyopathy
2017 · Alexandr Yagoda, Natalia Gladkikh, et al. · Medical news of the North Caucasus · 1
PDF
Works count: 40
Citation count: 242
H-index: 10
I10-index: 10
Year
Topic
Type